Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097004 | 1.00 | HSD11B1 (0.41) | HSD11B1MEN1ALDH1A1GAAHPGD | |
| SCHEMBL4094929 | 0.96 | HSD11B1 (0.45) | HSD11B1 | |
| SCHEMBL4094928 | 0.96 | HSD11B1 (0.45) | HSD11B1 | |
| SCHEMBL4102221 | 0.89 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL4102218 | 0.89 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL4094867 | 0.86 | HSD11B1 (0.36) | HSD11B1 | |
| SCHEMBL4094861 | 0.86 | HSD11B1 (0.36) | HSD11B1 | |
| SCHEMBL4103439 | 0.84 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL4103435 | 0.84 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL4097931 | 0.83 | HSD11B1 (0.47) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885MEN1 2335/4885ALDH1A1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.